17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
12 feb - 
Novo A/S/bestyrelsesformand: Kolding er fyret ..
09 feb - 
Aktier/åbning: Vestas til tops i comeback og Pandora ti..
09 feb - 
Sanofi har ventet tilbagegang i diabetesforretningen ..
Relateret debat
12 feb - 
Nej - og det takker jeg Skaberen for hver aften...
12 feb - 
Enig
12 feb - 
Sludder! I december kunne vi ikke forudse det nuvæ..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
10 feb
NOVO-B
Hallo.... Novo har været den mest stabile aktie i de sidste 20 år. Dette her en god mulighed for at ..
5
09 feb
NOVO-B
Hvad sker der hos Novo. Hvordan kan de forgylde Kåre med 71 millioner kroner for at fyre ham. Er der..
4
07 feb
NOVO-B
Langliggeren, du kan så få mit trend-beslutningsgrundlag for min egen handel   Der er røde, gule og ..
4
06 feb
NOVO-B
Så AUs bud er, at enten vil det falde eller også vil det stige. Den slags visdom kan jeg godt forstå..
4
06 feb
NOVO-B
Hvad så her og hvad så der.. - Det var jo netop mine oplevelser i fortiden jeg prøvede at dele ud af..
4
09 feb
NOVO-B
En mand, der får så meget for at gå, må virkelig være ringe ...  
3
07 feb
NOVO-B
"Resultat af primær drift steg med 14% i lokale valutaer justeret for salg af NNIT"   "Salget steg m..
3
07 feb
NOVO-B
Klogeligt har jeg som newbie holdt lav profil og suget til mig fra de gamle håndværksmestre. Jeg fin..
3
06 feb
NOVO-B
Jeg synes også se "vrøvler" og kommer med den ene selvmodsigelse efter den anden (som de meget ofte ..
3
12 feb
NOVO-B
en enkelt ligegyldig detalje. Danske købte i Finland og Irland mange år før Kolding blev headhuntet ..
2

OVERBLIK FLS: Service lyser op i en meget, meget mørk tid

11-02-2016 16:10:04
I det mørke, som ingeniørkoncernen FLSmidths aktuelt er indhyldet i på mine- og cementmarkedet er det serviceforretningen i divisionerne Product Companies og Cu..

Topdk Q4: Vejrligsskader overrasker og skuffer analytikerne

11-02-2016 12:41:58
Forsikringskoncernen Topdanmark kom ud af fjerde kvartal sidste år med et nettooverskud på 278 mio. kr., hvilket var ringere end analytikernes forventninger.Ifø..

Mærsk/Jyske: Skærer i kursmål efter regnskab - NY

11-02-2016 10:40:38
Jyske Bank har været inde og se på de langsigtede forventningerne til aktien i A.P. Møller-Mærsk, og det får nu banken til at skære 1000 kr. af kursmålet til 90..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo A/S/bestyrelsesformand: Kolding er fyret
2
Globale aktiemarkeder i selvforstærkende negativ spiral
3
Tyskland/Nykredit: Tysk økonomi bliver gyser i 2016
4
Aktier/tendens: GN tager fokus på dag med udsigt til stigninger
5
Vestas: Vinder 200 MW-ordre til projekt i USA

Relaterede aktiekurser

Novo Nordisk B A/S 321,20 1,0% Stigning i aktiekurs
Novo-Nordisk A/S 48,80 0,4% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2016  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
13. februar 2016 01:24:52
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20160212.1 - EUROWEB6 - 2016-02-13 01:24:52 - 2016-02-13 01:24:52 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x